Other

Albany Medical College

David R Nalin

Edmund J Gosselin

Sudeep Kumar

Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.

Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens

A method immunizing an individual that minimizes the amount of antigen or attenuated organism needed and the number of doses and clinic visits required, while making possible polyvalent simultaneous immunizations. The method comprises the steps of obtaining a sample of blood. Exposing at least a portion of this sample to at least one immunogenic antigen, attenuant or other immunogen. Incubating the exposed sample under specified optimal conditions and introducing this exposed sample into the individual to effect immunization thereof. The method of the invention also provides a method of delivery of materials, other than antigens, throughout an individual's body such as therapeutic drugs, virus vectors, genes, DNA, RNA, isotopes, and other therapeutic substances. A method for the delivery of treatment material to an individual is also provided by this method.

Method of medically treating an individual

A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge is provided for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second plunger and at least one microtubule member containing one of a treatment agent and a vaccine antigen. At least one open end formed within the at least one microtubule member for drawing a portion of the buffy coat therein and exposing the buffy coat to one of the treatment agent and vaccine antigen. A second needle capable of being attached onto the second syringe for introducing the exposed sample into the individual to effect treatment/vaccination thereof. This system is capable of allowing a plurality of treatment agents and/or vaccine antigens to be simultaneously applied to an individual.

Growing community of inventors

West Chester, PA, United States of America

David R Nalin